共 25 条
- [4] Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis [J]. Rheumatology and Therapy, 2020, 7 : 165 - 171
- [7] Tocilizumab (TCZ) Monotherapy is Superior to Adalimumab (ADA) Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis (RA): 24-Week Data from the Phase 4 ADACTA Trial [J]. JOURNAL FUR MINERALSTOFFWECHSEL, 2012, 19 (03): : 138 - 138
- [9] The AMBITION study: Superiority of tociluzumab (TCZ) vs methotrexate (MTX) monotherapy in patients with rheumatoid arthritis (RA) [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S618 - S618